WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 22, 1080-1091. Review Article ISSN 2277–7105

"REVIEW ON MANAGEMENT OF INSOMNIA: THE SILENT STRUGGLE"

Phatake Divya Sanjay*, Chopade B. L. and Dr. Megha Salve[1]

Shivajirao Pawar College of Pharmacy Pachegaontal. Newasa Dist. Ahmednagar 413725.

Article Received on
01 October 2024,

Revised on 22 October 2024,
Accepted on 11 Nov. 2024

DOI: 10.20959/wjpr202422-34677

***Corresponding Author**
Phatake Divya Sanjay
Shivajirao Pawar College of Pharmacy Pachegaon tal. Newasa Dist. Ahmednagar 413725.

➢ ABSTRACT

Insomnia is a common sleep disorder characterized by difficulty initiating or maintaining sleep, leading to daytime impairment. It affects approximately 10-30% of the general population, with higher prevalence among women, older adults, and individuals with mental health conditions. Insomnia can be acute or chronic, with various underlying causes, including stress, lifestyle factors, and underlying medical conditions. Cognitive behavioral therapy for insomnia (CBT-I) and pharmacological interventions are effective treatments, but relapse rates are high. the treatment include Anti-depressant, benzodiazepines and intake of melatonin contains milk alsoeffective. Further research is needed to understand insomnia's pathophysiology and develop personalized treatment approaches to improve sleep quality and quality of life**.**

KEYWORDS: Insomnia, sleep disorder, pharmacological intervention.

➢ INTRODUCTION

Early adulthood is a tough time in life compared to being a teenager or in your 30s and 40s. This is because people in their 20s and early 30s have to deal with a lot of hard stuff, like figuring out their careers and dealing with social issues.[1,2] The prevalence of general sleep disturbances is high. Over a year, about 85%[3] of people were engaged. The number of people with chronic insomnia is thought to be around 200,000.Other estimates have found this to be higher. In 2002, the United States National Health Interview Survey revealed that 87 percentof Americans had never had a health interview. 17.4% of adults with self- reported asthma. Having trouble sleepingbecause of insomnia or mood changes.

Female anxiety disorders are slightly morecommon than male anxiety disorders.

Males with primary sleeplessness.[4] *Mental well-being health issue in general population*-self-declared indications of psychiatric issues showed up to be especially tall among the Swiss common populace, and crests were watched for people in late puberty and early adulthood and among females. If you don't mind note that the definition of rising or youthful adulthood between 18 and 25 a long time may change between disciplines of pharmaceutical or brain research and creator[5] *Mental well-beinghealth in student* If we consider symptomsof social anxiety as the opposite pole of social activity, the following observations were made: Hazmi, et al.[6] reported a prevalence rate of 13.5% among Saudi medical students, and Alkhali fah, et al. ntal well-being issue in student.[7]

- **Pathophysiology**

A sleeping disorder comes about due to an lopsidedness between rest actuating neurotransmitters gamma-aminobutyric corrosive (GABA) and adenosine show within the ventrolateral preoptic core within the hypothalamus and the excitement neurotransmitters (noradrenaline, serotonin, acetylcholine, orexin and dopamine)[9] O rex m moreover known as hypocretin, may be, which is liberated by a cluster of neurons within the horizontal hypothalamus. It moreover shows up to be included within the control of attentiveness. Rest disabling impact of caffeine is thought to be due to barricade of adenosine A2-receptors. Numerous of the particles included in sleep-wake control are delivered by particular brain structures with far reaching projections all through the brain. There IS, in any case, mounting prove that numerous rest administrative particles influence neurons locally, within the locales in which they are delivered. In neighborhood rest hypothesis proposed by Krueger et al,[10] once an person starts to involvement rest troubles, stress and rumination move from life occasions to stresses almost rest itself and approximately the daytime results of not getting sufficient rest. This negatively- toned cognitive action is assist fueled in the event that a sleep-related danger is recognized or a rest shortfall is seen.

Physiological excitement has been assessed through estimations of the entire body metabolic rate, heart rate changeability, neuroendocrine measures, and utilitarian neuroimaging. Entirety body metabolic rate may be measured by oxygen utilization (VO2). Later ponders compared great sleepers with patients analyzed with a sleeping disorder. The sleep deprivation patients exhibited altogether higher metabolic rates (measured at interims over the 24-hour day) than the solid controls.[11] The neuroendocrine framework may moreover

give prove of excitement as illustrated by inveterate actuation of the stretch response framework. A few thinks about measuring 24-hour urinary free cortisol excretion have found tall levels in destitute sleepers[12,13] Insomnia is associated with many medical conditions, including heart disease, cancer, neurological disorders, chronic urinary tract disorders, gastrointestinal disorders, and chronic pain.[14,15] Up to 40% of those affected have been diagnosed with mental illnesses such as depression, anxiety disorders and post-traumatic stress disorder.[15]

- **Symptoms**

1. Having a hard time falling asleep at night
2. Waking up during the night.
3. Waking up too early.
4. Feeling tired or sleepy during the day.
5. Feeling cranky, depressed or anxious.
6. Having a hard time paying attention, focusing on tasks or remembering.
7. Making more errors or having moreaccidents.
8. Having ongoing worries about sleep.

- **Risk factors**

Age: You can develop insomnia at any agebut your chances of having it increase as you get older.

Family history and genetics: Your genes may raise your risk of insomnia, as insomnia sometimes runs in families. Your genes may also affect whether you are a deep or light sleeper.

Stress*:* Stress or worrying about school orwork, relationships, money, or the death of a loved one raises your risk of insomnia. Worrying about whether you will get enough sleep and watching the clock can also raise your risk of insomnia or make it worse.

Sex*:* Insomnia is more common in women than in men. hormone changes that take place during pregnancy and menopause can cause problems with sleep.[16]

- **Classification**



- **Treatment of insomnia**

pharmacological therapies

Benzodiazapins

These agents do this modification by binding to a specific site on the GABA-A receptor complex (called the benzodiazepine binding site), thus changing the structure of the receptor's binding proteins, and increase resistance. It occurs when GABA binds to these receptors.[18,19] This increased inhibition is associated with a number of dose- dependent clinical effects, including sedation, anxiety reduction, seizure prevention, and hypothermia.[17,18,20]

Z- Drugs

These agents are an unrelated group of compounds which act by the same mechanism as benzodiazepines, but does not share the benzodiazepine chemical structure.[17] There is some evidence that they may differ somewhat from benzodiazepines in that their action is relatively restricted to subsets of GABA-A receptors. As result, that may have less broad clinical effects.[21]

Melatonin receptor antagonist

There are two melatonin receptor agonists used to treat insomnia: melatoninand ramelton is a hormone used by many people with insomnia. Normally, the pineal gland releases it during the darkest part of the day. It primarily binds to MT1 and MT2 receptors, although the mechanism by which it improves sleep is not fully understood.[22]

Anti depressant

The most common antidepressants used to treat insomnia are trazodone 50-150 mg, doxepin 10-75 mg, mirtazapine 15 mg and amitriptyline 10-100 mg In at least one randomized, double-blind, placebo- controlled study, this study was limited.

Many medications originally developed to treat major depressive disorder are used to treat insomnia. These agents can produce sleep-enhancing effects by blocking receptors for neurotransmitters such as norepinephrine, histamine, acetylcholine and serotonin.[23]

Antipsychotic drug

These agents may be therapeutically effective in insomnia due to their broad antagonism at excitatory neurotransmitterreceptors such as dopamine, histamine, serotonin, cholinergic, and adrenergic receptors. Because there is no risk of abuse of these agents, it is possible to consider using people who are prone to abuse. However, it is good for insomnia in patients with mental illness or bipolar disorder.[24]

Anticonvulsants

Certain medications are sometimes used to treat insomnia. These include gabapentin and pregabalin, whose therapeutic effects on insomnia are attributed to a reduction in the release of glutamate and norepinephrine through binding to the alpha-2-delta component of calcium channels. N-type voltage.[25, 26]

Non selective antihistaminic agent

There is very little data showing the insomnia effect of these drugs. The therapeutic effect of diphenhydramine 50mg on the number of awakenings, but not on sleep quality, total sleep time, or sleep onset, was reported in A cross-sectional study in 20 elderly patients with primary insomnia.[27]

- **Non pharmacological treatmentCongestive behavioral therapy**

For people whose insomnia doesn't go away, non-pharmacological treatment is seen to be the best option because it has been proven to work. 27–29 Patients choose cognitive behavioral treatment (CBT-i) over medication therapy for insomnia because it enhances sleep outcomes with little side effects.[28]

Chronic insomnia, particularly those with co-morbidities, is advised to be treated with cognitive behavioral therapy (CBT-i), which targets dysfunctional beliefs and behaviors that underlie insomnia.27 Six to eight individual or group sessions typically make up therapy. However, it comes withdrawbacks, such as potential issues with access and the availability of facilitators with the necessary training. Internet- based CBT-i is a potentially useful substitute for in-person CBT-i.[29] Because they help the patient and the treating therapist see progress, sleep diaries are typically maintained during therapy.18 Studies have demonstrated that CBT-i has fewer adverse effects and performs better than hypnotic drugs.[30] To maximize sleep gains, CBT-i must be used in conjunction with adequate care of underlying medical and psychiatric conditions.10. Future concerns include raising patient awareness and accessibility to CBT-i, as it is advised as a first-line treatment for insomnia.[31]

- **Plant Use in Management ofinsomnia**

***Valerian*:** Studies have shown that the effectiveness of Valerian in treating sleep disorders varies widely, ranging from 200 to 1000 mg doses. Yet, there's no definitive research on the optimal dosage for Valerian in individuals with long-term sleep problems. A study by Zare et al.[32] found that Valerian was successful in treating chronic sleep disorders. Similarly, a different study by Shinjyo et al[33] found that Valerian reduced the time it takes to fall asleep, enhanced the time spent awake after sleep, and also increased the overall duration of sleep**.**

Fig. Valerian

Chamomile: Traditional medicine has used chamomile to treat issues related to sleep. Chamomile is an excellent treatment for chronic insomnia because it contains flavonoids and

apigenin, which can bind to benzodiazepine receptors in the brain and promote a tranquilizing effect.[34]

According to Zick et al. chamomile can greatly enhance sleep quality, especially for senior insomniac patients. They stated that utilizing 270 mg of chamomile for four weeks was ineffective in enhancing sleep onset delay, wake after sleep onset time**,** sleep length, nocturnal awakening**,** daytime performance, and sleep quality.[35]

Kava kava

Fig. *Chamomile*

Jumps are thought to associated with melatonin receptors, and they are frequently combined with other operators such as valerian. Right now, accessible prove recommends that a combination item counting bounces and valerian may progress rest inactivity as compared to a fake treatment after 28 days of treatment.[38]

From the root. Piper methysticum, which is used for its calming and aphrodisiac properties, stimulatory effects, especially in the South Pacific area[36] Kavakava contains a wide range of active substances, The kava pyranones are the best known among them. as kavain, desmethoxyyangostin, yangonins. dihydromethystin, methystin and dihydrokapara. But Unfortunately, we do not know the names of them. Responsible for all anxiolytic properties.[37]

Fig. Kava Kava

Hops: Hops are another broadly utilized nervine relaxant. The blossoming strobiles of the female bounces plant contain tall concentrations of dynamic standards humulone and lupul one that stay show within the dried herb. The normal dosage is 0.5 grams of the dried herb arranged as atea or as a dry extricate.

Fig. Hops

Suanzaoren: In a clinical study of 300 individuals with insomnia, Wang and colleagues(2022) found that SZRD led to improvements in sleep quality as well as anxiety and depression symptoms. SZRD, atreatment for insomnia that is still widely used today, was originally described in the Synopsis of the Golden Chamber by Zhongjing Zhang during the Eastern Han Dynasty.[39]

- **Role of pharmacist in patientcounselling for insomnia**

Pharmacists are in a unique position to recognize medications and co-morbidities that are linked to or may make insomnia worse.[40] Patients can record how long ittakes them to fall asleep, how often they wake up during the night, and how they feel when they wake up by keeping a sleep diary of their morning and evening activities. Other activities, such as exercise, coffee and medicine intake, and the time the patient had dinner, can also be included in the sleep diary.43 After determining the underlying reason or causes of insomnia, pharmacists can be crucial in establishing treatment objectives and recommending non-pharmacological ways to manage sleepdisturbances and enhance sleep patterns.[41]

When it comes to pharmaceutical management, patients with co-occurring disorders like anxiety or depression could need additional attention. The length of time it may take for antidepressants to take effect should be discussed with thosetaking them.[42]

The pharmacist should inform all patients receiving pharmaceutical treatment for insomnia, whether they are taking prescription or over-the-counter medications, on potential side effects, drug interactions, contraindications, and extra precautions.[41]

REFERENCE

1. Havighurst, R.J. Developmental Tasks and Education; McKay: New York, NY, USA, 1953.
2. Buss, D.M. Evolutionary Psychology. The New Science of the Mind, 6th ed.; Routledge: New York, NY, USA, 2019.
3. Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences.Clinical Cornerstone:Chronic Insomnia, 2003; 5(3): 5e15.
4. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 national health interview survey data. Arch Intern Med., Sep 18 2006; 166(16): 1775e82.
5. Arnett, J.J. Emerging adulthood. A theory of development from the late teens through the twenties. Am. Psychol., 2000; 55: 469–480.[CrossRef] [PubMed
6. Al-Hazmi, B.H.; Sabur, S.S.; Al-Hazmi, R.H. Social anxiety disorder in medical students at Taibah University, Saudi Arabia.J. Family Med. Prim. Care, 2020; 9: 4329–4332. [CrossRef]
7. Alkhalifah, A.K.; Alsalameh, N.S.; Alhomaidhy, M.A.; Alrwies, N.A. Prevalence of Social Phobia among Medical Students inSaudi Arabia. Egypt. J. Hosp. Med., 2017; 69: 2412–2416. [CrossRef]
8. https://www.mayoclinic.org/diseases- conditions/.insomnia/symptoms- causes/syc-20355167
9. Arya SN, Rajiv K, Singh R. Practical Approach to the Diagnosis and Management of Insomnia, Ch114, Sec16,519.
10. Krueger JM, Rector DM, Roy S, Van Dongen HP, et al. Sleep as a fundamental property of neuronal assemblies. Nat Rev Neurosci., 2008; 9(12): 910-919.
11. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med., 1998; 60: 610-5.
12. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Mastorakos G, Vela-Bueno A, Kales A, Chrousos GP. Chronic insomnia is associated with nyctohemeral activation of thehypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab., 2001; 86: 3787-94.
13. Vgontzas AN, Tsigos C, Bixler EO, Stratakis CA, Zachman K, Kales A, Vela-Bueno A, Chrousos GP. Chronic insomnia and activity of the stress system: a preliminary study. J Psychosom Res., 1998; 45: 21-31.
14. Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, Bush AJ. Comorbidity

of chronic insomnia with medical problems. Sleep., 2007 Feb; 30(2): 213-8. doi: 10.1093/sleep/30.2.213. Erratum in: Sleep. 2007 Jul 1; 30(7): table of contents. PMID: 17326547.

15. Mai E, Buysse DJ. Insomnia: Prevalence, Impact, Pathogenesis, Differential Diagnosis, and Evaluation. Sleep Med Clin., 2008; 3(2): 167-174. doi: 10.1016/j.jsmc.2008.02.001. PMID: 19122760; PMCID: PMC2504337.
16. https://www.nhlbi.nih.gov/health/insomnia/causes
17. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. New York: McGraw-Hill Medical, 2009.
18. Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes, Curr Top MedChem., 2002; 2: 795-816.
19. Krogsgaard-Larsen P, Frolund B, Liljefors T. Specific GABA(A) agonists and partial agonists. Chem Rec., 2002; 2: 419-30.
20. Morin CM, Drake CL, Harvey AG et al. Insomnia disorder. Nat Rev Dis Primers, 2015; 1: 15026.
21. Morin CM, Drake CL, Harvey AG et al. Insomnia disorder. Nat Rev Dis Primers, 2015; 1: 15026.
22. Ng KY, Leong MK, Liang H et al. Melatonin receptors: distribution in mammalian brain and their respective putative functions. Brain Struct Funct., 2017; 222: 2921-39.
23. Krystal AD. A compendium of placebo- controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev., 2009; 13: 265-74.
24. Chakravorty S, Hanlon AL, Kuna ST et al. The effects of quetiapine on sleep in recovering alcohol-dependent subjects: a pilot study. J Clin Psychopharmacol, 2014; 34: 350-4.
25. Rose M, Kam CA. Gabapentin: pharmacology and its use in pain manage- ment. Anaesthesia, 2002; 57: 451-62.
26. Gajraj N. Pregabalin: its pharmacologyand use in pain management. Anesth Analg., 2007; 105: 1805-15.
27. Glass JR, Sproule BA, Herrmann N et al. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol., 2008; 28: 182-8.
28. Trauer JM, Qian MY, Doyle JS, et al. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Annals of Internal Medicine, 2015 Aug 4; 163(3):

191204.

29. Outhoff K. Insomnia disorder: a harddday's night. SA Pharmaceutical Journal, 2016 Jan 1; 83(1): 14-6.
30. Anderson KN. Insomnia and cognitivebehavioural therapy-how to assess your patient and why it should be a standard part of care. J Thorac Dis., 2018 Jan; 10(Suppl 1): S94-S102. doi:10.21037/jtd.2018.01.35.
31. Geiger-Brown JM, Rogers VE, Liu W, Ludeman EM, et al. Cognitive behavioral therapy in persons with comorbid insomnia: A meta-analysis. Sleep Med Rev., 2015 Oct; 23: 54-67. doi:10.1016/j.smrv.2014.11.007.
32. Zare Elmi H.K. Gholami M., saki M., et al efficiency Valerian Extract on sleep quality after coronary artery bypass graft surgery:A triple blind randomized controlled trial chin j. Integr.
33. ShinjyoN, waddell G, Green J valerian root intrating sleep problems and associateddisorder A systematic review and meta analysis.
34. Jia, Y., Zou, J., Wang, Y., Zhang, X., Shi,Y., Liang, Y, et al. Action mechanism of Roman chamomile in the treatment of anxiety disorder based on network pharmacology. Journal of Food Biochemistry, 2021; 45(1): e13547. DOI: 10.1111/jfbc.13547.
35. Zick S. M, Wright B. D, Sen A, Arnedt J. T.Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronicprimary insomnia: a randomized placebo-controlled pilot study. BMC Complementary and Alternative Medicine, 2011; 11(1): 78. doi:10.1186/1472-6882-11-78.
36. Aporosa S. A. De-mythologizing and re-branding of kava as the new 'world drug' of choice. Drug Science, Policy and Law, 2019; 5: 205032451987613. DOI: 10.1177/2050324519876131.
37. Barguil Y, Choblet E, Warter S, et al. Kava A nitric oxide synthase inhibition? Annales De Toxicologie Analytique., 2013; 25: 165–168. DOI: 10.1051/ata/2014001.
38. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo- controlled clinical trial. Sleep., 2005; 28(11): 1465-1471.17. Natural Standard Database. Hops.
39. Exploring the mechanism of Suanzaoren decoction in treatment of insomnia based on network pharmacologyand molecular docking by Shuxiao Wang, Yan Zhao, Xingang Hu.
40. Ross M (Ed). 5 sleep tips for insomnia patients. Pharmacy Times. Practice Information for To-day's Pharmacist. 7 March 2016. Available fromhttp://www.pharmacytimes.com/ne ws/5sleep-tips-for-insomnia-patients?p=2

(Accessed 27 February 2018).

41. University of California Berkeley. Sleep Self-care Guide. Available from: https://uhs.berke- ley.edu/sites/default/files/insomnia.pdf (Accessed 27 February 2018).